S
huzo Kure, the first to describe paroxysmal kinesigenic dyskinesia (PKD) in a Japanese journal in 1892, 1 would have been pleased to learn that the gene for this condition has now been identified. 2, 3 Paroxysmal kinesigenic dyskinesia is the most common paroxysmal movement disorder, presenting with brief episodes of dystonic, choreatic, or ballistic, and sometimes bizarre, involuntary movements triggered by sudden movement with onset in childhood or adolescence. 4 Owing to its unusual semiology, PKD is often misdiagnosed as a psychogenic disorder. However, it is easily treatable with low doses of anticonvulsants. 4 Notably, PKD has been clinically and genetically linked to a variety of heterogeneous and, at first sight, unrelated conditions. This includes benign familial infantile seizures (BFIS); the syndrome of rolandic epilepsy, paroxysmal exercise-induced dyskinesia, and writer's cramp; and even the trait of wet ear wax (cerumen). 1, 4 Indeed, the co-occurrence of BFIS and PKD in families has resulted in the identification of another illness, infantile convulsions and paroxysmal choreo-athetosis (ICPC). 1, 4 Benign familial infantile seizures may be one of the most common forms of epilepsy that develop in the first 2 years of life and is characterized by nonfebrile convulsions with onset at between 3 and 12 months of age. 5 Seizures are focal, with or without secondary generalization, occurring in clusters and often resulting in cyanosis. The disorder leads to considerable anxiety among parents and doctors who are unfamiliar with it, but it also responds reliably to carbamazepine and has a benign prognosis. 5 Mutations in the proline-rich transmembrane protein 2 (PRRT2) gene, which is located within the previously linked region on chromosome 16, have been identified as the cause of PKD and ICPC. 2, 3, 6 We screened the entire PRRT2 gene for mutations in 3 families with ICPC and 1 family with PKD-3 of German and 1 of Turkish-Russian descent. Neuropediatricians reviewed the patients, and the diagnoses of PKD and BFIS were based on established criteria. 4, 5 All affected members had typical features of PKD and/or BFIS and were identified with the previously reported heterozygous truncating c.649dupC (p.R217PX8) mutation. 2, 3, 6 Notably, this mutation was found in 3 individuals with isolated BFIS, 6 patients with pure PKD, 3 with both BFIS and PKD, and 1 nonmanifesting carrier ( Figure) . Genotyping of these pedigrees showed 4 independent haplotypes, suggesting that this mutation arose from recurrent mutational events. These results confirm that PRRT2 mutations cause PKD and ICPC in multi-ethnic populations including German, Turkish, and Russian. Most importantly, they provide further evidence that the 2 apparently clinically distinct syndromes of BFIS and PKD can be allelic conditions, and they can both be caused by the same mutation in PRRT2.
There has been debate about whether paroxysmal dyskinesias have an epileptic origin. 1, 4 It is notable that in PKD, ictal and interictal changes are typically absent on electroencephalogram. 1, 4 However, the confirmation that PKD and BFIS can have a shared genetic cause lends support to the concept that the pathophysiological mechanism underlying PKD may be subcortical epileptogenic discharges, possibly originating from the basal ganglia. The molecular pathway may involve synaptic regulation via interactions with the SNAP25 protein, ultimately leading to neuronal hyperexcitability. 6 These findings are of interest to a broad range of clinicians who may encounter patients presenting with infantile convulsions or PKD. Paroxysmal kinesigenic dyskinesia should be suspected in families with a child with BFIS and vice versa. There is now evidence to suggest that a simple genetic test (sequencing of the small PRRT2 gene) may replace laborious and expensive diagnostic investigations in these patients. The finding of PRRT2 mutations in families with isolated BFIS without cooccurring PKD has been a recent development, further expanding the phenotypic spectrum. 
COMMENTS AND OPINIONS

Insulin and Alzheimer Disease
T he article by Craft et al 1 demonstrating that intranasal insulin improves cognitive function and fludeoxyglucose F 18 uptake in specific regions of the brain in patients with mild cognitive impairment and Alzheimer disease (AD) is a landmark study. For the first time, the previous data that AD is both a reflection of a combination of diminished insulin bio-availability and insulin action has been borne out. In addition, the data are consistent with the fact that AD is a chronic inflammatory disease and that insulin exerts a potent antiinflammatory effect. 2 More recently, it has also been shown that insulin suppresses the expression of genes related to AD: amyloid precursor protein, presenilins 1 and 2, and glycogen synthase kinase-3␤ in peripheral blood mononuclear cells. 3 These actions could potentially limit the formation of ␤-amyloid and the intracellular neurofibrillary tangles. While these observations were not made in neurons, they were obtained in humans in vivo with doses and concentrations of insulin that are therapeutically relevant. It is possible that intranasally administered insulin achieves sufficiently high intracerebral concentrations of insulin to suppress the expression of the genes just mentioned.
In this context, it is also relevant that the amyloid precursor protein has recently been shown to be expressed in vascular tissue where it may, along with ␤-amyloid, exert pro-inflammatory and potential pro-atherogenic effects. Thus, the effects of insulin are relevant both at the cerebral and vascular levels.
Clearly, larger long-term studies are required to establish the use of intranasal insulin in the treatment of AD. Additionally, specific biomarkers are readily obtainable samples and easy to measure, and those that are highly responsive to therapy are clearly needed. However, it is clear that a door has been opened for the rational treatment of this hitherto almost untreatable disease with a drug that has practically no adverse effects other than hypoglycemia. This effect can be avoided by its intranasal
